Kinfo
Bellevue Life Sciences Acquisition Corp. logo

Bellevue Life Sciences Acquisition Corp.

BLACNASDAQFinancial Services·US · USD
$0.44
+0.01 (+1.56%)
Prices as of August 7, 2026 · market closed

Price

Key statistics

Valuation
Market cap2.47M USD
Enterprise value0.00 USD
Trailing P/E540.50
Forward P/E0.00
PEG ratio-0.77
Price / sales0.00
Price / book0.12
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets1.10%
Return on equity1.24%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income403.78K USD
Diluted EPS$0.05
Rev. growth (YoY)0.00%
Balance sheet
Total cash12.24K USD
Total debt0.00 USD
Debt / equity0.00
Current ratio0.01
Book value / share$3.69
Cash flow (TTM)
Operating cash flow-1.34M USD
Levered free cash flow403.78K USD
Shares & price
Shares outstanding4.04M
Float0.00
Held by institutions0.00%
Beta0.00
50-day MA$0.00
200-day MA$0.00
52-week high$1.24
52-week low$0.30
Earnings (EPS)
DateEst.ActualSurprise2026-07-161.101.17+6.36%2026-06-11-0.33-0.09+72.73%
About Bellevue Life Sciences Acquisition Corp.

Bellevue Life Sciences Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with a business in the life sciences sector. Designed to facilitate companies seeking public investment without undergoing a traditional Initial Public Offering (IPO), it raises capital through its own initial listing to fund potential acquisition targets. Bellevue Life Sciences Acquisition Corp. primarily targets industries such as biotechnology, pharmaceuticals, medical devices, and diagnostic services, which are pivotal for advancing healthcare solutions and technological innovations in medicine. The company leverages its leadership's expertise in navigating complex public markets and facilitating strategic growth for its chosen partner. As a SPAC, its significance in the financial market lies in its ability to provide a streamlined path for life sciences companies to access public capital, thereby accelerating research, development, and commercialization efforts in critical health-related fields. Through its structured approach, Bellevue Life Sciences Acquisition Corp. plays a vital role in expanding investment opportunities and fostering advancement in the high-demand area of life sciences.

Sector
Financial Services
Industry
Shell Companies
CEO
Mr. Kuk Hyoun Hwang
Headquarters
Bellevue, WA, United States

Frequently asked questions about Bellevue Life Sciences Acquisition Corp.